Valuation: Monopar Therapeutics Inc.

Market Cap 782M 675M 635M 577M 1.09B 74.92B 1.1B 7.45B 2.92B 37.47B 2.94B 2.87B 125B P/E 2026 *
-46.7x
P/E 2027 * -46.5x
Enterprise Value 663M 573M 539M 490M 921M 63.54B 935M 6.32B 2.48B 31.78B 2.49B 2.44B 106B EV / Sales 2026 *
-
EV / Sales 2027 * 22.6x
Free-Float
76.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.67%
1 week+2.42%
Current month+8.20%
1 month+10.70%
3 months+108.42%
6 months+111.31%
Current year+79.53%
1 week 107.78
Extreme 107.78
118.2
1 month 101
Extreme 101
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 29.18
Extreme 29.18
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+2.42%+242.19%+3,521.72% 782M
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.25%+4.32%+488.29%+623.94% 45.44B
+1.58%+2.50%+15.32%+90.76% 41.22B
+0.42%-0.64%+25.83%+13.23% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+1.97%-0.88% - - 16.25B
-1.24%-2.55%+27.47%+136.32% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-1.60%-0.06%+79.53%+41.69% 13.68B
Average -0.03%-0.69%+100.13%+503.64% 26.93B
Weighted average by Cap. +0.10%-0.84%+103.87%+163.72%

Financials

2026 *2027 *
Net sales - 28.26M 24.41M 22.96M 20.87M 39.26M 2.71B 39.83M 269M 106M 1.35B 106M 104M 4.51B
Net income -21.46M -18.54M -17.44M -15.85M -29.82M -2.06B -30.25M -205M -80.18M -1.03B -80.59M -78.84M -3.43B -26.62M -22.99M -21.63M -19.66M -36.97M -2.55B -37.52M -254M -99.43M -1.28B -99.93M -97.76M -4.25B
Net Debt -119M -103M -96.51M -87.71M -165M -11.38B -167M -1.13B -444M -5.69B -446M -436M -18.96B -145M -125M -117M -107M -201M -13.85B -204M -1.38B -540M -6.93B -543M -531M -23.07B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
18/08/26 $117.64 +0.99% 75,454
17/08/26 $116.49 +3.05% 171,114
14/08/26 $113.04 +2.38% 165,721
13/08/26 $110.41 -3.91% 162,521
12/08/26 $114.90 +0.38% 354,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
116.49USD
Average target price
126.31USD
Spread / Average Target
+8.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock